Background: Candida species are the third most common cause of pediatric health care–associated bloodstream infection in the United States and Europe. To our knowledge, this report from the ...

Background: Invasive candidiasis is an increasing problem in neonatal intensive care units worldwide and is an important cause of morbidity, mortality and prolongation of hospital stay. Despite ...

Invasive candidiasis, which in many patients represents a life-threatening condition, is “largely a disease of medical progress,” according to the Guidelines. Risk factors include the use of ...

Invasive candidiasis represents a spectrum of life-threatening fungal infections that commonly afflict critically ill patients. It encompasses candidemia—bloodstream invasion by Candida species—and ...

SAN DIEGO & CAMBRIDGE, England--(BUSINESS WIRE)--Cidara Therapeutics, Inc. (NASDAQ: CDTX) and Mundipharma today announced positive topline data from the pivotal ReSTORE Phase 3 clinical trial ...

Rezafungin is a next-generation, once-weekly echinocandin being developed for both the treatment and prevention of serious fungal infections, such as invasive candidiasis and candidemia The European ...

Michail Lionakis, MD, ScD, chief of the fungal pathogenesis section at the National Institutes of Health, is the senior author of this study. Invasive candidiasis is a life-threatening fungal ...

SAN DIEGO, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing therapies designed to save lives and improve the standard of care for patients ...

Researchers at the Weizmann Institute of Science in Israel have identified a yeast that could be used to prevent invasive candidiasis, a major cause of death in hospitalized and immunocompromised ...

A yeast infection is pesky, yet very common. It's estimated that about three out of four women will experience at least one vaginal yeast infection in their lifetime. Yeast infections are caused by ...

The study primary endpoint was met, showing non-inferiority vs. standard antimicrobial regimen in fungal-free survival at Day 90 Study showed favourable benefit for toxicity-related discontinuations ...